These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

986 related items for PubMed ID: 21858220

  • 1. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
    Lee JY, Lee YM, Chang GC, Yu SL, Hsieh WY, Chen JJ, Chen HW, Yang PC.
    PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
    [Abstract] [Full Text] [Related]

  • 2. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
    Zhang Y, Yao K, Shi C, Jiang Y, Liu K, Zhao S, Chen H, Reddy K, Zhang C, Chang X, Ryu J, Bode AM, Dong Z, Dong Z.
    Oncotarget; 2015 Dec 29; 6(42):44274-88. PubMed ID: 26517520
    [Abstract] [Full Text] [Related]

  • 3. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S.
    Mol Cancer Ther; 2012 Oct 29; 11(10):2149-57. PubMed ID: 22844075
    [Abstract] [Full Text] [Related]

  • 4. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death.
    Chen P, Huang HP, Wang Y, Jin J, Long WG, Chen K, Zhao XH, Chen CG, Li J.
    J Exp Clin Cancer Res; 2019 Jun 13; 38(1):254. PubMed ID: 31196210
    [Abstract] [Full Text] [Related]

  • 5. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
    Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, Lifshits E, Byers LA, Xu L, Wu HK, Jänne P, Kobayashi S, Halmos B, Tenen D, Tang XM, Engelman J, Yeap B, Folkman J, Johnson BE, Heymach JV.
    Clin Cancer Res; 2009 May 15; 15(10):3484-94. PubMed ID: 19447865
    [Abstract] [Full Text] [Related]

  • 6. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
    Smith DL, Acquaviva J, Sequeira M, Jimenez JP, Zhang C, Sang J, Bates RC, Proia DA.
    Target Oncol; 2015 Jun 15; 10(2):235-45. PubMed ID: 25077897
    [Abstract] [Full Text] [Related]

  • 7. Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo.
    Zhu H, Cheng H, Ren Y, Liu ZG, Zhang YF, De Luo B.
    Mol Biol Rep; 2012 Apr 15; 39(4):4971-9. PubMed ID: 22160570
    [Abstract] [Full Text] [Related]

  • 8. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
    Takezawa K, Okamoto I, Tanizaki J, Kuwata K, Yamaguchi H, Fukuoka M, Nishio K, Nakagawa K.
    Mol Cancer Ther; 2010 Jun 15; 9(6):1647-56. PubMed ID: 20530710
    [Abstract] [Full Text] [Related]

  • 9. Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer.
    Sudo M, Chin TM, Mori S, Doan NB, Said JW, Akashi M, Koeffler HP.
    Cancer Chemother Pharmacol; 2013 May 15; 71(5):1325-34. PubMed ID: 23515752
    [Abstract] [Full Text] [Related]

  • 10. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
    Li A, Cao W, Liu X, Zhang Y, Ma Y, Xu R, Zhang R, Liu X, Zhou S, Wang R, Liu J, Tang X.
    J Cancer Res Clin Oncol; 2020 Jul 15; 146(7):1737-1749. PubMed ID: 32342201
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F, Zhu T, Cao B, Wang J, Liang L.
    Eur J Cancer; 2017 Oct 15; 84():184-192. PubMed ID: 28822888
    [Abstract] [Full Text] [Related]

  • 14. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
    Dong S, Zhang XC, Cheng H, Zhu JQ, Chen ZH, Zhang YF, Xie Z, Wu YL.
    Cancer Chemother Pharmacol; 2012 Nov 15; 70(5):707-16. PubMed ID: 22941374
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.
    Yoshida T, Zhang G, Smith MA, Lopez AS, Bai Y, Li J, Fang B, Koomen J, Rawal B, Fisher KJ, Chen YA, Kitano M, Morita Y, Yamaguchi H, Shibata K, Okabe T, Okamoto I, Nakagawa K, Haura EB.
    Clin Cancer Res; 2014 Aug 01; 20(15):4059-4074. PubMed ID: 24919575
    [Abstract] [Full Text] [Related]

  • 17. Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells.
    Cao W, Liu Y, Zhang R, Zhang B, Wang T, Zhu X, Mei L, Chen H, Zhang H, Ming P, Huang L.
    Sci Rep; 2015 Jul 13; 5():8477. PubMed ID: 26166037
    [Abstract] [Full Text] [Related]

  • 18. Clathrin-mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild-type EGFR non-small cell lung cancer.
    Kim B, Park YS, Sung JS, Lee JW, Lee SB, Kim YH.
    Cancer Med; 2021 Jan 13; 10(1):372-385. PubMed ID: 33314735
    [Abstract] [Full Text] [Related]

  • 19. Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization.
    Yeung YT, Yin S, Lu B, Fan S, Yang R, Bai R, Zhang C, Bode AM, Liu K, Dong Z.
    EBioMedicine; 2018 Feb 13; 28():51-61. PubMed ID: 29398601
    [Abstract] [Full Text] [Related]

  • 20. Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer.
    Noto A, De Vitis C, Roscilli G, Fattore L, Malpicci D, Marra E, Luberto L, D'Andrilli A, Coluccia P, Giovagnoli MR, Normanno N, Ruco L, Aurisicchio L, Mancini R, Ciliberto G.
    Oncotarget; 2013 Aug 13; 4(8):1253-65. PubMed ID: 23896512
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.